138 related articles for article (PubMed ID: 16937392)
1. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
Law JK; Ali JA; Harrigan PR; Sherlock CH; Savage KJ; Yoshida EM
Am J Hematol; 2006 Dec; 81(12):969-72. PubMed ID: 16937392
[TBL] [Abstract][Full Text] [Related]
2. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
Ahmed A; Keeffe EB
Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
[TBL] [Abstract][Full Text] [Related]
5. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
van der Eijk AA; Doorduijn JK; Janssen HL; Schalm SW; Niesters HG; de Man RA
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1140-4. PubMed ID: 12092307
[TBL] [Abstract][Full Text] [Related]
6. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
Amini-Bavil-Olyaee S; Hosseini SY; Sabahi F; Alavian SM
Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
[TBL] [Abstract][Full Text] [Related]
8. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
9. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
11. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
[TBL] [Abstract][Full Text] [Related]
13. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ
Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742
[TBL] [Abstract][Full Text] [Related]
15. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Kohrt HE; Ouyang DL; Keeffe EB
Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
[TBL] [Abstract][Full Text] [Related]
16. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
17. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
[TBL] [Abstract][Full Text] [Related]
19. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
20. [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
Shtalrid M; Haran M; Klepfish A; Lurie Y; Malnick S
Harefuah; 2001 Dec; 140(12):1159-62, 1230, 1229. PubMed ID: 11789300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
